SCHEMBL4851322

SCHEMBL4851322

COc1cccc(Cn2cc(Br)c3ccncc32)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPO P22079 3/20 0.47
ROCK2 O75116 5/20 0.45
KCNH2 Q12809 1/20 0.45
DYRK1A Q13627 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ROCK1 Q13464 1/20 0.45
KDM4C Q9H3R0 2/20 0.45
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
CMA1 P23946 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CDK2 P24941 1/20 0.42
DYRK1B Q9Y463 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4857751 0.85 ROCK2 (0.47) ROCK2KCNH2DYRK1AROCK1KDM4C
SCHEMBL4857531 0.81 DYRK1A (0.66) KCNH2DYRK1AMEN1KMT2AKDM4C
SCHEMBL29801631 0.81 DYRK1A (0.66) KCNH2DYRK1AMEN1KMT2AKDM4C
SCHEMBL4849408 0.79 DYRK1A (0.53) KCNH2DYRK1AKDM4CCDK2DYRK1B
SCHEMBL4857588 0.79 CYP19A1 (0.50) ROCK2KCNH2DYRK1AMEN1KMT2A
SCHEMBL4859131 0.77 FNTA (0.46) DYRK1AALDH1A1
SCHEMBL20147188 0.75 MAOA (0.54) ROCK2MEN1KMT2AMAPTLMNA
SCHEMBL4847918 0.75 DYRK1A (0.52) KCNH2DYRK1AKDM4CCDK2DYRK1B
SCHEMBL4855301 0.75 DYRK1A (0.43) ROCK2KCNH2DYRK1AMEN1KMT2A
SCHEMBL20604702 0.74 LPO (0.45) LPOMEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 LPO 4771/4885ROCK2 483/4885KCNH2 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.